Get started
Author

Lukas Kevličius

Observed names: Kevličius, Lukas, L. Kevlicius, L. Kevličius, Lukas Kevlicius
ORCID: 0000-0003-3536-3701
Observed ORCID: 0000-0003-3536-3701
OpenAlex ID: A5057811810
Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature
2020 · Mingaile Drevinskaite, Ausvydas Patasius, et al. · BMC Cancer · 38
PDF
New in vitro model evaluating antiseptics’ efficacy in biofilm-associated Staphylococcus aureus prosthetic vascular graft infection
2019 · Elvyra Staneviciute, Wasef Na’amnih, et al. · Journal of Medical Microbiology · 18
Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV ‐2 Omicron in patients with haematological malignancies: A national prospective cohort study
2023 · Lukas Kevličius, Karolis Šablauskas, et al. · British Journal of Haematology · 8
Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies
2022 · Lukas Kevlicius, Ruta Cepulyte, et al. · Bone Marrow Transplantation · 4
Frontline Sequential Allogeneic Stem Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia with 3q26.2/Mecom Rearrangement
2024 · Andrius Žučenka, Lukas Kevličius, et al. · Blood · 2
Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia
2025 · Andrius Zucenka, Milda Mikalonyte, et al. · Blood · 1
PDF
Individualized Sequential Allogeneic Stem Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Patients with Active Disease
2024 · Andrius Zucenka, Lukas Kevličius, et al. · Blood · 1
Neutralization profile of SARS‐CoV ‐2 omicron BA .1 variant in high binding titer plasma
2022 · Lukas Kevlicius, Dovile Juozapaite, et al. · Transfusion · 1
AML-998: Outcomes of Consolidative Allogeneic Transplantation After Venetoclax Plus Hypomethylating Agent Induction in Acute Myeloid Leukemia: A Single-Center Retrospective Study
2026 · Milvydė Tamutytė-Jankauskė, Milda Mikalonytė, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-998: Outcomes of Consolidative Allogeneic Transplantation After Venetoclax Plus Hypomethylating Agent Induction in Acute Myeloid Leukemia: A Single-Center Retrospective Study
2026 · Milvydė Tamutytė-Jankauskė, Milda Mikalonytė, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-783: Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study
2026 · Milda Mikalonyte, Milvyde Tamutyte -Jankauske, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-783: Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study
2026 · Milda Mikalonytė, Milvydė Tamutytė-Jankauskė, et al. · Clinical Lymphoma Myeloma & Leukemia
Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement
2026 · Milda Mikalonytė, Vilhelmas Landsbergis, et al. · Frontiers in Oncology
PDF
Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts-2
2025 · Andrius Zucenka, Lukas Kevlicius, et al. · Blood
AML-535: Gilteritinib in Combination With Venetoclax, Low-Dose Cytarabine, and Actinomycin D As Salvage Therapy for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (FLT3m R/R AML): A Single-Center Retrospective Study
2025 · Milda Mikalonyte, Tautvile Smalinskaite, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-535 Gilteritinib in Combination With Venetoclax, Low-Dose Cytarabine, and Actinomycin D As Salvage Therapy for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (FLT3m R/R AML): A Single-Center Retrospective Study
2025 · Milda Mikalonytė, Tautvilė Smalinskaitė, et al. · Clinical Lymphoma Myeloma & Leukemia
783 | Place‐of‐care Produced Fresh Formulation Mb‐cart19.1 Cell Therapy for Relapsed or Refractory Cd19+ Hematological Malignancies With Central Nervous System Involvement
2025 · S. Cernauskiene, A. Bukauskas, et al. · Hematological Oncology
PDF
AML-700 Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB
2024 · Tautvilė Smalinskaitė, Lukas Kevličius, et al. · Clinical Lymphoma Myeloma & Leukemia
Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)
2024 · Lukas Kevličius, Tautvilė Smalinskaitė, et al. · Clinical Lymphoma Myeloma & Leukemia
Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB
2024 · Tautvilė Smalinskaitė, Lukas Kevličius, et al. · Clinical Lymphoma Myeloma & Leukemia
Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients
2023 · Andrius Zucenka, Birutė Davainienė, et al. · Blood
Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting
2022 · Andrius Žucenka, Lukas Kevličius, et al. · Blood
P592: Gilteritinib in Combination With Venetoclax, Low Dose Cytarabine and Actinomycin D for Flt3 Mutated Relapsed or Refractory Acute Myeloid Leukemia
2022 · A. Žučenka, R. Pileckytė, et al. · HemaSphere
Works count: 25
Citation count: 73
H-index: 4
I10-index: 2
Year
Topic
Type